Enhanced Survival in Advanced Breast Cancer with New PIK3CA-Targeted Treatment Combination
A groundbreaking phase 3 trial reveals that combining inavolisib with palbociclib and fulvestrant significantly prolongs survival in patients with PIK3CA-mutated advanced breast cancer, offering new hope through precision medicine.
Recent clinical research has demonstrated promising advancements in the treatment of advanced breast cancer characterized by PIK3CA mutations, which are present in approximately 35-40% of hormone receptor–positive cases. A significant phase 3 trial, led by researchers at Mass General Brigham, evaluated the effectiveness of a three-drug regimen combining inavolisib, palbociclib, and fulvestrant. The study revealed that patients receiving this combination experienced increased overall survival times, with a median of 34 months compared to 27 months in the control group. Additionally, these patients showed longer periods without disease progression (17.2 months vs. 7.3 months) and higher tumor reduction rates (62.7% vs. 28.0%). The treatment regimen received FDA approval last October based on favorable progression-free survival data, emphasizing its potential as a new standard for this subset of breast cancer patients.
Despite its benefits, the combination was associated with some notable side effects, including elevated blood sugar levels, mouth sores, diarrhea, and eye issues. Serious adverse events occurred in 27.3% of patients, leading to discontinuation in 6.8%, highlighting the importance of monitoring and managing side effects. The research team plans further studies to assess safety and efficacy in underrepresented groups, such as older adults over 65.
These findings underscore the importance of PIK3CA mutation testing in advanced breast cancer and support the integration of precision oncology approaches to improve patient outcomes. The study's results were published in the "New England Journal of Medicine" and presented at the ASCO annual meeting. The promising effects of this combination mark a significant step forward in targeted breast cancer therapies, offering hope for enhanced survival rates in this patient population.
Source: https://medicalxpress.com/news/2025-06-drug-combination-survival-patients-pik3ca.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Experts Urge Medical Consultation Before Trying Water-Only Fasting Diets
Experts warn that water-only fasting diets can pose health risks, especially for individuals with existing conditions. Consult your healthcare provider before attempting prolonged fasting to ensure safety and understand potential effects.
New Findings Challenge Beliefs About Dancers and Vestibular Suppression During Pirouettes
A new study reveals that dancers' ability to perform pirouettes is not due to suppressing their vestibular system but relies on active, anticipatory control of balance through brain plasticity. This discovery could inform improved fall prevention strategies.
New Guidelines Emphasize the Role of Quality of Life Assessments in Advanced Cancer Care
A new policy review in The Lancet Oncology highlights the critical role of health-related quality of life assessments in advanced cancer clinical trials, promoting patient-centered outcomes and standardized reporting for better care.